Highlights from Recent Cancer Literature

出处
期刊:Cancer Research [American Association for Cancer Research]
卷期号:81 (19): 4887-4888
标识
DOI:10.1158/0008-5472.can-81-19-bi
摘要

The serine/threonine liver kinase B1 (LKB1) is a tumor suppressor and a well-established activator of AMPK kinases involved in cellular meta-bolism. In addition to restricting tumor growth, LKB1 has also been shown to limit the metastatic potential of tumor cells, but it is unclear if this is dependent on AMPK. Pierce and colleagues described a novel function of this kinase by showing that LKB1 regulates chromatin accessibility, mediated via the SIK family of kinases in lung cancer. High levels of the transcription factor SOX17 and increased accessibility of genomic regions that contain SOX motifs correlated with metastatic progression in LKB1-deficient mouse lung adenocarcinomas. Interestingly, some primary lung tumors contained a metastatic-like population of SOX17+ cells, with SOX17 being sufficient to drive epigenetic changes in LKB1-deficient cells that drive metastases.Expert Commentary: The identification of epigenetic differences in primary tumors and metastatic lesions driven by LKB1 loss highlights the ability of individual genetic alterations to differentially alter cancer phenotypes at different stages of disease progression.Pierce SE, Granja JM, Corces MR, Brady JJ, Tsai MK, Pierce AB, et al. LKB inactivation modulates chromatin accessibility to drive metastatic progression. Nat Cell Biol 2021;23:915–24.In response to therapeutics, a subset of cancer cells enters a reversible drug tolerant state through mechanisms that have not been fully described. The majority of “persister cells” remain quiescent, but some are able to proliferate despite the presence of cancer therapeutics, presenting a mechanism by which tumors can obtain drug resistance. Oren and colleagues used a novel barcoding lentiviral system to simultaneously trace the growth and gene expression patterns of persister cell lineages at different time points following treatment with the EGFR inhibitor osmertinib. They showed that cycling and noncycling persister cells arose from different cell lineages, and cycling persister cells exhibited an increased antioxidant program and fatty acid metabolism. Importantly, modulating these programs altered the number of cycling persister cells. Cells with similar properties were found in multiple types of drug-treated tumor cells, mouse models, and patient tumors.Expert Commentary: The identification of novel biological programs that regulate cycling persister cells, which drive drug resistance in multiple types of cancer, could enable novel ways to prevent such resistance.Oren Y, Tsabar M, Cuoco M, Amir-Zilberstein L, Cabanos HF, Hütter JC, et al. Cycling cancer persister cells arise from lineages with distinct programs. Nature 2021;596:576–82.Small cell lung cancer (SCLC) is an aggressive and deadly, with limited effective therapies. However, there is increasing evidence that altered epigenetic remodeling is a key driver of this disease and could present a therapeutic target. Following previous work demonstrating a role for the BAP1/ASXL3/BRD4 epigenetic axis in SCLC, Zhao and colleagues used a genome-wide CRISPR-Cas9 screen to identify paired box protein 9 (PAX9) as a downstream transcriptional target upregulated by this chromatin remodeling complex. PAX9 is a transcription factor, however, the authors observed low occupancy of PAX9 at gene promoters and identified PAX9 was almost exclusively localized to primed enhancers in SCLC. Functionally, PAX9 interacts with components of the nucleosome remodeling and deacetylase (NuRD) complex to restrict expression of tumor suppressor genes, which could be reversed by either genetic depletion of PAX9 or pharmacological HDAC inhibition.Expert Commentary: This study provides mechanistic insights into the oncogenic function of the PAX9/NuRD complex in human SCLC and suggests reactivation of primed enhancers as a treatment for SCLC expressing high levels of PAX9.Zhao Z, Szczepanski AP, Tsuboyama N, Abdala-Valencia H, Goo YA, Singer BD, et al. PAX9 determines epigenetic state transition and cell fate in cancer. Cancer Res 2021;81:4696–708.Despite evidence that pancreatic ductal adenocarcinoma (PDAC) cells express tumor-specific antigens, the use of immunotherapy has been largely ineffective as a treatment option for this disease, suggesting PDAC cells upregulate mechanisms to evade immune detection. Freed-Pastor and colleagues analyzed PDAC whole exome data and found nearly all cancers contain mutationally derived neoantigens predicted to bind MHC class I. However, freshly isolated human PDAC revealed CD8+ T cells with an exhausted phenotype. Additionally, employing an organoid-based transplantation model and an autochthonous model of PDAC, they showed that tumors expressing model neoantigens were either edited (losing neoantigen expression) or progressed while maintaining neoantigen expression. The authors examined immune inhibitory ligand expression in human PDAC and found CD155 to be highly expressed, and the authors demonstrated CD155 and its co-inhibitory receptor TIGIT could promote PDAC immune evasion. Combined treatment of orthotopic tumors with anti-CD40, anti-PD1, and anti-TIGIT provided durable tumor remissions, while no single or dual treatment was effective.Expert Commentary: Blocking the CD155/TIGIT immune inhibitory axis in combination with other checkpoints overcomes PDAC immune evasion and reduces tumor burden in preclinical models.Freed-Pastor WA, Lambert LJ, Ely A, Pattada NB, Bhutkar A, Eng G, et al. The CD155/TIGIT axis promotes and maintains immune evasion in neoantigen-expressing pancreatic cancer, Cancer Cell 2021:S1535-6108(21)00384-6. doi: 10.1016/j.ccell.2021.07.007.Multiple myeloma, the second most common hematological cancer, develops in the bone marrow due to uncontrolled proliferation of malignant plasma cells. The Notch signaling pathway is dysregulated in multiple myeloma and this favors pathological communication between multiple myeloma and bone marrow cells. Gamma-secretase inhibitors (GSI) are used extensively to inhibit Notch in multiple myeloma, however, GSIs can cause undesirable, dose-limiting severe toxicities, restricting clinical application. Sabol and colleagues generated a bone-targeted Notch inhibitor (BT-GSI) which was targeted to the bone via a bisphosphonate group and contained a linker group that could be cleaved in the acidic environment in the bone to release the GSI. The authors demonstrated that systemic administration of BT-GSI selectively inhibits Notch signaling in bone/bone marrow but not in other tissues, overcoming the toxicity issues associated with this class of drugs. In mouse models of established multiple myeloma, BT-GSI inhibited multiple myeloma growth and bone destruction more effectively than the GSI aloneExpert Commentary: This study reports a bone-targeted BT-GSI that reduced multiple myeloma growth, diminished cancer-induced bone destruction, and did not induce gut or hematological toxicities typically found with systemic administration of GSIs.Sabol HM, Ferrari AJ, Adhikari M, Amorim T, McAndrews K, Anderson J, et al. Targeting Notch inhibitors to the myeloma bone marrow niche decreases tumor growth and bone destruction without gut toxicity. Cancer Res 2021;81:5102–14.The efficacy of EGFR targeted therapy is limited by the development of acquired resistance in non-small cell lung cancer. Resistance to EGFR inhibitors, such as osimertinib, frequently arises via non-EGFR–dependent mechanisms, so there is a need to identify therapies that can be combined with EGFR inhibitors to clear resistant tumor cells. Utilizing a high-throughput screening approach, with selection for compounds that enhanced osimertinib-induced apoptosis, Tanaka and colleagues demonstrated that targeting Aurora B kinase (AURKB) could enhance osimertinib-induced apoptosis and overcome resistance. AURK inhibitors were found to increase BIM and PUMA levels, resulting in increased osimertinib sensitivity and decreased drug-tolerant persisters. ATR-CHK1-AURKB pathway inhibition could also overcome epithelial-mesenchymal transition–associated resistance through mitotic cell death.Expert Commentary: This study suggests that selecting osimertinib combination therapies that enhance apoptosis may improve duration of response and overcome resistance in the clinic.Tanaka K, Yu HA, Yang S, Han S, Selcuklu SD, Kim K, et al. Targeting Aurora B kinase prevents and overcomes resistance to EGFR inhibitors in lung cancer by enhancing BIM- and PUMA-mediated apoptosis. Cancer Cell 2021; S1535–6108(21)00383-4. doi: 10.1016/j.ccell.2021.07.006.Note: Breaking Insights are written by Cancer Research editors. Readers are encouraged to consult the articles referred to in each item for full details on the findings described.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
1秒前
carol0705完成签到,获得积分10
1秒前
深情安青的应助被Levonpox采纳,获得10
1秒前
1秒前
超级棒完成签到 ,获得积分10
2秒前
ll完成签到,获得积分10
2秒前
箫涵完成签到,获得积分10
2秒前
好好吃饭完成签到 ,获得积分10
2秒前
zn666完成签到 ,获得积分10
2秒前
3秒前
打打的应助被爱科研的小民采纳,获得10
3秒前
quanchengBjcp发布了新的文献求助10
3秒前
Nole的应助被彩色山柏采纳,获得30
3秒前
巧可脆脆完成签到,获得积分10
3秒前
wwj发布了新的文献求助10
4秒前
oreo完成签到,获得积分10
4秒前
Juvenilesy的应助被1101592875采纳,获得10
4秒前
广东下不了一点雪完成签到,获得积分10
4秒前
whddue完成签到,获得积分10
5秒前
WWWJ完成签到,获得积分10
5秒前
chonghuang发布了新的文献求助10
5秒前
cdercder的应助被心房的锁采纳,获得30
5秒前
bkagyin的应助被ZM采纳,获得10
6秒前
小马甲的应助被科研通管家采纳,获得30
6秒前
interest-li完成签到,获得积分10
6秒前
bkagyin的应助被科研通管家采纳,获得10
6秒前
SHANELIU完成签到 ,获得积分10
6秒前
无花果的应助被科研通管家采纳,获得10
6秒前
爆米花的应助被科研通管家采纳,获得10
6秒前
hhh发布了新的文献求助10
7秒前
kayzhu完成签到,获得积分10
7秒前
7秒前
Maestro_S的应助被科研通管家采纳,获得10
7秒前
7秒前
今后的应助被科研通管家采纳,获得10
7秒前
FashionBoy的应助被科研通管家采纳,获得10
7秒前
7秒前
完美世界的应助被科研通管家采纳,获得10
7秒前
无花果的应助被科研通管家采纳,获得10
7秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Boundaries and Bodhisattvas 500
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8181279
求助须知:如何正确求助?哪些是违规求助? 9571198
关于积分的说明 21817073
捐赠科研通 7777612
什么是DOI,文献DOI怎么找? 3433454
关于科研通互助平台的介绍 2557692
邀请新用户注册赠送积分活动 2479519